BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Long Term Debt

Track Apimeds Pharmaceuticals US's long-term debt ($100K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$101873.00

Peer trimmed avg / median

Loading

Apimeds Pharmaceuticals US Long Term Debt History

Loading

Apimeds Pharmaceuticals US vs. peers: Long Term Debt Comparison

Loading

Apimeds Pharmaceuticals US Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

As of the most recent data (June 2026), APUS shows a long-term debt of $100K. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APUS's long-term debt is now $100K (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Apimeds Pharmaceuticals US is outperforming or lagging.

Tracking APUS's long-term debt over time shows whether Apimeds Pharmaceuticals US is scaling, shrinking, or reshaping that part of the business. The current reading is $100K In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Apimeds Pharmaceuticals US's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $100K) with ownership activity and broader fundamentals.